Table 1.
PICOS strategy for data extraction of novel glycopeptides.
Fig 1.
PRISMA flow diagram of the meta-analysis.
Table 2.
Characteristics of included trials in meta-analysis.
Fig 2.
Clinical response of novel glycopeptides against vancomycin in the modified intent-to-treat populations.
Fig 3.
Clinical response of novel glycopeptides against vancomycin in the clinical evaluable populations.
Fig 4.
Clinical response of novel glycopeptides against vancomycin in the microbiological evaluable populations with MRSA.
Fig 5.
Adverse events of novel glycopeptides against vancomycin in the modified intent-to-treat populations.
Fig 6.
Serious adverse events of novel glycopeptides against vancomycin in the modified intent-to-treat populations.
Fig 7.
Discontinuation of novel glycopeptides against vancomycin due to adverse events in the modified intent-to-treat population.
Fig 8.
Mortality rate related to novel glycopeptides against vancomycin in the modified intent-to-treat population.
Table 3.
Summary of specific adverse events compared between novel glycopeptides and vancomycin.
Fig 9.
Funnel plot, using data from 11 trials of novel glycopeptides therapy in patients with gram positive cocci.